Important Publications

Abdalla J, Langer A, Elzahwy SS, Arman-Kalcek G, Streichert T, Quitterer U. Angiotensin-converting enzyme (ACE) inhibition down regulates the pro-atherogenic chemokine receptor 9 (CCR9) - chemokine ligand 25 (CCL25) axis. J. Biol. Chem., 2010, 285, 23496-23505. GEO accession no. GSE19286

• Selected by NCBI as GEO profile (GDS3683) with presentation on 2256 pages
• http://www.ncbi.nlm.nih.gov/geoprofiles?term=GDS3683[ACCN]

AbdAlla S, Lother H, Langer A, el Faramawy Y, Quitterer U. Factor XIIIA transglutaminase crosslinks AT₁ receptor dimers of monocytes at the onset of atherosclerosis. Cell, 2004, 119, 343-354.

• Preview: Ogawa S, Glass CK. Factor XIIIA (cross)links AT₁ receptors to atherosclerosis. Cell, 2004, 119, 313-314.
• Commentary: Thomas WG. Double trouble for type 1 angiotensin receptors in atherosclerosis. New. Engl. J. Med., 2005, 352, 506-508.
• Data added to the "Biomolecular Interaction Network Database" (BIND)
  
  

Lorenz K, Lohse MJ, Quitterer U. PKC switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature, 2003, 426, 574-579.

• Commentary: Goel, R., Baldassare, J. J. Killing two birds with one RKIP. Trends. Endocrinol. Metab., 2004, 15, 91-92.
• Data added to the "Biomolecular Interaction Network Database" (BIND)
  
  

AbdAlla S, Lother H, Massiery A, Quitterer U. Increased AT₁ receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nature Medicine, 2001, 7, 1003-1009.

• News and Views: Lodwick D. Receptor double-trouble in preeclampsia. Nature Medicine, 2001, 7, 999-1000.
  
  

AbdAlla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature, 2000, 407, 94-98.

• Highly cited paper (Top 1 % of the field according to ISI Web of Science)